Akorn (NASDAQ: AKRX) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Akorn to similar companies based on the strength of its profitability, valuation, institutional ownership, risk, dividends, analyst recommendations and earnings.
This is a breakdown of recent ratings and price targets for Akorn and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Akorn presently has a consensus target price of $30.14, suggesting a potential downside of 9.67%. As a group, “Pharmaceuticals” companies have a potential upside of 25.68%. Given Akorn’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Akorn has less favorable growth aspects than its competitors.
This table compares Akorn and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Akorn and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Akorn||$1.12 billion||$184.24 million||33.71|
|Akorn Competitors||$8.17 billion||$1.09 billion||167.86|
Akorn’s competitors have higher revenue and earnings than Akorn. Akorn is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
68.7% of Akorn shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.2% of Akorn shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Akorn has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Akorn’s competitors have a beta of 36.02, indicating that their average share price is 3,502% more volatile than the S&P 500.
Akorn competitors beat Akorn on 8 of the 13 factors compared.
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.